<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00461773</url>
  </required_header>
  <id_info>
    <org_study_id>0609001793</org_study_id>
    <nct_id>NCT00461773</nct_id>
  </id_info>
  <brief_title>Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer</brief_title>
  <official_title>Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the objective response rate of a combination of
      letrozole (Femara) and bevacizumab (Avastin) given preoperatively to postmenopausal patients
      with hormone sensitive breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2007</start_date>
  <completion_date type="Anticipated">May 2010</completion_date>
  <primary_completion_date type="Anticipated">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess clinical objective tumor response with 14 weeks of neoadjuvant letrozole combined with bevacizumab</measure>
    <time_frame>Upon completion of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess breast conservation rates (actual surgery performed and baseline feasible surgery) of 14 weeks of neoadjuvant letrozole combined with bevacizumab</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess radiographic tumor response (ultrasound, mammogram, MRI) after 14 weeks of neoadjuvant letrozole combined with bevacizumab</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess pathologic complete response after 14 weeks of neoadjuvant letrozole combined with bevacizumab</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate response with biological correlates detected at baseline and after 1 cycle of treatment with either bevacizumab alone or bevacizumab combined with letrozole</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the tolerability of 14 weeks of neoadjuvant letrozole combined with bevacizumab</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hormone-Sensitive Breast Cancer</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>brief exposure bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>brief exposure bevacizumab and letrozole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Letrozole 2.5 mg po qd</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>bevacizumab 10 mg/kg IV</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed operable or potentially operable invasive breast
             adenocarcinoma that is clinically palpable and measurable

          -  Age ≥ 18 years

          -  Clinical Stage T2-4, N0-3, M0 (Stage II-III)

          -  Postmenopausal defined as Age ≥ 60 years and/or Age &gt;45 years with amenorrhea 12
             months with an intact uterus and/or History of bilateral oophorectomy and/or FSH and
             estradiol levels in postmenopausal range

          -  ECOG PS 0, 1

          -  Unifocal disease

          -  ER and/or PR positive

          -  Adequate hematological, renal, and hepatic functions Absolute neutrophil count ≥
             1,500/µL Platelet count ≥ 100,000/µL creatinine ≤ 1.5 mg/dL Serum total bilirubin ≤
             1.5 mg/dL Alkaline phosphatase ≤ 3X the ULN for the reference lab SGOT/SGPT ≤ 3X the
             ULN for the reference lab

          -  Patients or their legal representatives must be able to read, understand and provide
             informed consent to participate in the trial

          -  Use of effective means of contraception (men and women) in subjects of child-bearing
             potential

        Exclusion Criteria:

          -  Prior history of and/or therapy for invasive breast cancer (includes chemotherapy,
             radiation, hormonal therapy including AIs, tamoxifen, raloxifene, fulvestrant or any
             other antiestrogen/SERM)

          -  Clinically significant cardiovascular disease, EF &lt;50%

          -  Known CNS disease

          -  History of deep vein thrombosis or pulmonary embolism

          -  Proteinuria at screening as demonstrated by either Urine protein:creatinine (UPC)
             ratio ≥ 1.0 at screening OR Urine dipstick for proteinuria ≥ 2+ (patients discovered
             to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour
             urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible).

          -  Presence of non-healing wound or fracture

          -  Current, recent (within 4 weeks of the first infusion of this study), or planned
             participation in an experimental drug study other than a Genentech-sponsored
             bevacizumab cancer study

          -  Inadequately controlled hypertension (defined as systolic blood pressure &gt;150 and/or
             diastolic blood pressure &gt; 100 mmHg on antihypertensive medications)

          -  Any prior history of hypertensive crisis or hypertensive encephalopathy

          -  New York Heart Association (NYHA) Grade II or greater congestive heart failure (see
             Appendix E)

          -  History of myocardial infarction or unstable angina within 12 months prior to study
             enrollment

          -  Any history of stroke or transient ischemic attack at any time

          -  Significant vascular disease (e.g., aortic aneurysm, aortic dissection)

          -  Symptomatic peripheral vascular disease

          -  Evidence of bleeding diathesis or coagulopathy

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to Day 0

          -  Core biopsy or other minor surgical procedures such as fine needle aspirations or core
             biopsies within 7 days prior to Day 0

          -  Pregnant (positive pregnancy test) or lactating. Use of effective means of
             contraception (men and women) in subjects of child-bearing potential is mandatory

          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
             within 6 months prior to Day 0

          -  Known hypersensitivity to any component of bevacizumab or letrozole

          -  Inability to comply with study and/or follow-up procedures
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gina Chung, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeannie Kluytenaar, RN</last_name>
    <phone>203-785-6523</phone>
    <email>jeannie.kluytenaar@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michele Alguard</last_name>
    <phone>203-737-5908</phone>
    <email>Michele.alguard@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale University, Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2007</study_first_submitted>
  <study_first_submitted_qc>April 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2007</study_first_posted>
  <last_update_submitted>June 5, 2009</last_update_submitted>
  <last_update_submitted_qc>June 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Gina Chung, M.D., Principal Investigator</name_title>
    <organization>Yale University School of Medicine</organization>
  </responsible_party>
  <keyword>Neoadjuvant treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

